Indian weight-loss market becomes ‘bloodbath’ as drugmakers pile in
- Posted on April 19, 2026
- By Financial Times
- 0 Views
In brief
India's weight-loss pharmaceutical sector faces intensifying competition as generic manufacturers prepare to launch affordable alternatives following the patent expiration of semaglutide, the active ingredient in Ozempic. This market disruption promises significant cost reduction for consumers while reshaping the competitive landscape for established drugmakers. The anticipated influx of generic versions signals a pivotal shift in accessibility to obesity treatments across the Indian subcontinent.
Indian weight-loss market becomes ‘bloodbath’ as drugmakers pile in
Consumers await cheaper generics after expiry of patent for Ozempic ingredient
